摘要
目的分析在脑梗死治疗中采用氯吡格雷联合氟伐他汀用药方式的临床治疗效果。方法以我院收治的脑梗死患者为研究对象,并随机将其分为观察组与对照组。对照组采用常规治疗,观察组在常规治疗的基础上采用氯吡格雷联合氟伐他汀进行治疗,比较其临床效果及其相关指标。结果对照组治疗显效17例(36.96%),有效19例(41.30%),无效10例(21.74%),治疗总有效率为78.26%(36/46);观察组治疗显效34例(73.91%),有效9例(19.57%),无效3例(6.52%),治疗总有效率为93.48%(43/46)。观察组的临床治疗总有效率明显高于对照组(P<0.05)。治疗后观察组的血脂指标(TC、TG、LDC-C和HDL-C),以及ADL评分、NIHSS评分改善幅度明显大于对照组(P<0.05)。结论采用氯吡格雷联合氟伐他汀治疗脑梗死能够有效缓解患者的临床症状,促进改善脑神经受损状况和预后状况,具有非常显著的临床疗效。
Objective To observe and analyze the clinical therapeutic effect of clopidogrel combined with fluvastatin in the treatment of cerebral infarction.Methods The patients with cerebral infarction in our hospital were randomly divided into observation group and control group.The control group was treated with conventional treatment,and the observation group was treated with clopidogrel combined with fluvastatin on the basis of conventional treatment.The clinical effects and related indicators were compared.Results In the control group,17 cases(36.96%)were markedly effective,19 cases(41.30%)were effective,and 10 cases(21.74%)were ineffective.The total effective rate was 78.26%(36/46).In the observation group,34 cases(73.91%)were markedly effective,9 cases(19.57%)were effective,and 3 cases(6.52%)were ineffective.The total effective rate was 93.48%(43/46).The total effective rate of clinical treatment in the observation group was significantly higher than that in the control group(P<0.05).After treatment,the improvement range of TC,TG,LDC-C,HDL-C,ADL score and NIHSS score in the observation group was significantly larger than that in the control group(P<0.05).Conclusion Clopidogrel combined with fluvastatin in the treatment of cerebral infarction can effectively relieve the clinical symptoms of patients,promote the improvement of cranial nerve damage and prognosis,and has very significant clinical efficacy.
作者
季恩飞
JI Enfei(Department of Neurology,Liaoyang Central Hospital,111000,China)
出处
《中国医药指南》
2021年第15期81-83,共3页
Guide of China Medicine
关键词
氯吡格雷
氟伐他汀
脑梗死
临床疗效
Clopidogrel
Fluvastatin
Cerebral infarction
Clinical efficacy